Companies often fall into common traps in early-stage product development. These range from interactions with the regulators to their ability to manufacture their product. Forward planning is crucial, but all too often smaller companies lack the regulatory, business development or marketing expertise needed to support this way of thinking. The podcast explores some of the pitfalls companies can fall into and ways to avoid them.
An expert in global drug development, Alex Klein has over 15 years of experience at some of the world’s leading organizations including Abbott, Abbvie, and Hospira, as well as various biotech startups. Her drug development experience includes both biologics and small molecules across multiple therapeutic areas. Possessing an understanding of what it takes to deliver new drugs to market, she has progressed several assets through development from preclinical through commercialization including supporting key regulatory agency meetings and submissions.